Evicenter
Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in Human papillomavirus vaccination
Manufacturer
Merck Sharp & Dohme LLC
Prescribing information
Gardasil 9 (opens in a new tab)
Questions
40
Last updated

All questions

Clinical trials: Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in human papillomavirus vaccination

13 questions · 2 sources

Study results

Gardasil 9 vs Gardasil in women 16-26: efficacy against HPV 31-58 disease?

Applies to Girls and women 16 through 26 years of age (Study 1, Gardasil 9 compared with Gardasil)

Did Gardasil 9 reduce HPV 31-58-related Pap abnormalities and procedures vs Gardasil?

Applies to Girls and women 16 through 26 years of age (Study 1, Gardasil 9 compared with Gardasil)

Gardasil 9 vs Gardasil: were antibody responses to HPV 6, 11, 16, 18 non-inferior?

Applies to Girls 9 through 15 years of age (Study 3) and girls and women 16 through 26 years of age (Study 1), Gardasil 9 compared with Gardasil

How was Gardasil 9 effectiveness inferred in children 9 to 15?

Applies to Girls and boys 9 through 15 years of age

How was 2-dose Gardasil 9 effectiveness inferred in ages 9 to 14?

Applies to Girls and boys 9 through 14 years of age given the 2-dose regimen (Study 8)

“Effectiveness of GARDASIL 9 against persistent infection and disease related to vaccine HPV types in 9- through 14-year-old girls and boys who received a 2-dose regimen was inferred from non-inferiority comparison conducted in the PPI population in Study 8 of GMTs following vaccination with GARDASIL 9 among 9- through 14-year-old girls and boys who received a 2-dose regimen (at 0, 6 months or 0, 12 months) with those among 16- through 26-year-old girls and women who received a 3-dose regimen (at 0, 2, 6 months). Anti-HPV GMTs at one month after the last dose among 9- through 14-year-old girls and boys who received 2 doses of GARDASIL 9 were non-inferior to anti-HPV GMTs among 16- through 26- year-old girls and women who received 3 doses of GARDASIL 9 (Table 12). One month following the last dose of the assigned regimen, between 97.9% and 100% of subjects across all groups became seropositive for antibodies against the 9 vaccine HPV types (Table 12). In the same study, in girls and boys 9 through 14 years old, GMTs at one month after the last vaccine dose were numerically lower for some vaccine types after a 2-dose schedule than in girls 9 through 14 years old after a 3-dose schedule (HPV types 18, 31, 45, and 52 after 0, 6 months and HPV type 45 after 0, 12 months; Table 12). The clinical relevance of these findings is unknown. Duration of immunity of a 2-dose schedule of GARDASIL 9 has not been established.” (opens the source at this quote in a new tab)

How was Gardasil 9 effectiveness inferred in males 16 to 26?

Applies to Boys and men 16 through 26 years of age (Study 7)

How was Gardasil 9 effectiveness supported in women 27 to 45?

Applies to Women 27 through 45 years of age (Study 9 immunobridging)

How effective was Gardasil, the predecessor of Gardasil 9, in women 16 to 26?

Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

Note: The label does not state the follow-up duration for the Table 6 trials.

How effective was Gardasil (predecessor vaccine) against genital and anal lesions in males 16-26?

Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

Note: The label does not state the follow-up duration for the Table 6 trials.

How effective was Gardasil (predecessor vaccine) in women 27 to 45?

Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

How was Gardasil (predecessor vaccine) effectiveness inferred in men 27 to 45?

Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

Long-term results

What did 10-year follow-up show after Gardasil 9 in ages 9 to 15?

Applies to Girls and boys 9 through 15 years of age

“In an extension study of individuals in Study 2, 971 girls and 301 boys 9 through 15 years of age at enrollment who received a 3-dose regimen of GARDASIL 9 were actively followed from age 16 onwards for endpoint cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related persistent infection and disease. For girls, disease endpoints assessed included HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58- related CIN (any grade), AIS, VIN, VaIN, external genital warts, cervical cancer, vulvar cancer and vaginal cancer. For boys, the disease endpoints assessed included HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related PIN, external genital warts, penile cancer, perineal cancer and perianal cancer. Analysis of the per-protocol population included 872 girls and 262 boys who completed the GARDASIL 9 vaccination series within one year, were seronegative to the relevant HPV type at initiation of the vaccination series and had not initiated sexual activity prior to receiving the third dose of GARDASIL 9. The median follow-up from the last dose of vaccine was 10.0 years with a range of 3.0 to 11.0 years in girls 9 through 15 years of age and 9.9 years with a range of 3.0 to 10.6 years in boys 9 through 15 years of age. In girls, no cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related CIN 2/3, AIS, VIN, VaIN, external genital warts, cervical cancer, vulvar cancer or vaginal cancer were observed over a total of 4,576.1 person-years at risk. One case of CIN1 that tested positive for HPV 16, 39 and 59 by PCR was observed. In boys, no cases of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related PIN, external genital warts, penile cancer, perineal cancer or perianal cancer were observed over a total of 1,278.6 person-years at risk.” (opens the source at this quote in a new tab)

What did long-term follow-up of Gardasil (predecessor vaccine) show?

Applies to GARDASIL (quadrivalent predecessor vaccine, HPV Types 6, 11, 16, and 18); the Gardasil 9 label states that its efficacy and effectiveness are relevant to Gardasil 9

“An extension study of 614 girls and 565 boys 9 through 15 years of age at enrollment who were randomized to vaccination with GARDASIL actively followed subjects for endpoint cases of HPV 6-, 11-, 16-, or 18-related persistent infection, CIN (any grade), AIS, VIN, VaIN, cervical cancer, vulvar cancer, vaginal cancer, and external genital lesions from the initiation of sexual activity or age 16 onwards. An interim analysis of the per-protocol effectiveness population included 246 girls and 168 boys who completed the GARDASIL vaccination series within one year, were seronegative to the relevant HPV type at initiation of the vaccination series, and had not initiated sexual activity prior to receiving the third dose of GARDASIL. The median follow-up from the first dose of vaccine was 7.2 years with a range of 0.5 to 8.5 years. At the time of interim analysis, no cases of persistent infection of at least 12 months’ duration and no cases of HPV 6-, 11-, 16-, or 18-related CIN (any grade), AIS, VIN, VaIN, cervical cancer, vulvar cancer, vaginal cancer, or external genital lesions were observed over a total 1,105 person-years at risk. There were 4 cases of HPV 6-, 11-, 16-, or 18-related persistent infection of at least 6 months’ duration, including 3 cases related to HPV 16 and 1 case related to HPV 6, none of which persisted to 12 months’ duration.” (opens the source at this quote in a new tab)